Management of metastatic castration-resistant prostate cancer

Research output: Contribution to journalArticle

Abstract

The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forwards in the last two years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel and abiraterone acetate) and a significant delay in skeletal-related events observed with denosumab. The pipeline of systemic therapies in prostate cancer remains strong, as multiple agents with a diverse array of mechanisms of action are demonstrating preliminary signs of clinical benefit, leading to more definitive Phase III confirmatory trials. In this review, we will discuss the evolving landscape of treatment options for men with CRPC, with a particular focus on currently approved and emerging treatment options for these patients. Knowledge of these evolving standards will help to optimise delivery of care and long-term outcomes in men with advanced CRPC.

Original languageEnglish (US)
Pages (from-to)90-97
Number of pages8
JournalEuropean Urological Review
Volume6
Issue number2
StatePublished - 2011

Fingerprint

Castration
Prostatic Neoplasms
Long-Term Care
Therapeutics
Survival

Keywords

  • Abiraterone
  • Cabazitaxel
  • Castration-resistant prostate cancer
  • Denosumab
  • Drug development
  • Ipilimumab
  • MDV3100
  • Novel therapies
  • Orteronel
  • Sipuleucel-T

ASJC Scopus subject areas

  • Urology

Cite this

Management of metastatic castration-resistant prostate cancer. / Antonarakis, Emmanuel.

In: European Urological Review, Vol. 6, No. 2, 2011, p. 90-97.

Research output: Contribution to journalArticle

@article{c2d7dd588c4341ecbb51b1b0ebced02a,
title = "Management of metastatic castration-resistant prostate cancer",
abstract = "The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forwards in the last two years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel and abiraterone acetate) and a significant delay in skeletal-related events observed with denosumab. The pipeline of systemic therapies in prostate cancer remains strong, as multiple agents with a diverse array of mechanisms of action are demonstrating preliminary signs of clinical benefit, leading to more definitive Phase III confirmatory trials. In this review, we will discuss the evolving landscape of treatment options for men with CRPC, with a particular focus on currently approved and emerging treatment options for these patients. Knowledge of these evolving standards will help to optimise delivery of care and long-term outcomes in men with advanced CRPC.",
keywords = "Abiraterone, Cabazitaxel, Castration-resistant prostate cancer, Denosumab, Drug development, Ipilimumab, MDV3100, Novel therapies, Orteronel, Sipuleucel-T",
author = "Emmanuel Antonarakis",
year = "2011",
language = "English (US)",
volume = "6",
pages = "90--97",
journal = "European Urological Review",
issn = "1758-3829",
publisher = "Touch Briefings",
number = "2",

}

TY - JOUR

T1 - Management of metastatic castration-resistant prostate cancer

AU - Antonarakis, Emmanuel

PY - 2011

Y1 - 2011

N2 - The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forwards in the last two years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel and abiraterone acetate) and a significant delay in skeletal-related events observed with denosumab. The pipeline of systemic therapies in prostate cancer remains strong, as multiple agents with a diverse array of mechanisms of action are demonstrating preliminary signs of clinical benefit, leading to more definitive Phase III confirmatory trials. In this review, we will discuss the evolving landscape of treatment options for men with CRPC, with a particular focus on currently approved and emerging treatment options for these patients. Knowledge of these evolving standards will help to optimise delivery of care and long-term outcomes in men with advanced CRPC.

AB - The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forwards in the last two years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel and abiraterone acetate) and a significant delay in skeletal-related events observed with denosumab. The pipeline of systemic therapies in prostate cancer remains strong, as multiple agents with a diverse array of mechanisms of action are demonstrating preliminary signs of clinical benefit, leading to more definitive Phase III confirmatory trials. In this review, we will discuss the evolving landscape of treatment options for men with CRPC, with a particular focus on currently approved and emerging treatment options for these patients. Knowledge of these evolving standards will help to optimise delivery of care and long-term outcomes in men with advanced CRPC.

KW - Abiraterone

KW - Cabazitaxel

KW - Castration-resistant prostate cancer

KW - Denosumab

KW - Drug development

KW - Ipilimumab

KW - MDV3100

KW - Novel therapies

KW - Orteronel

KW - Sipuleucel-T

UR - http://www.scopus.com/inward/record.url?scp=84871844954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871844954&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84871844954

VL - 6

SP - 90

EP - 97

JO - European Urological Review

JF - European Urological Review

SN - 1758-3829

IS - 2

ER -